GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
38.77
+1.63 (4.39%)
At close: Sep 18, 2024, 4:00 PM
40.66
+1.89 (4.87%)
After-hours: Sep 18, 2024, 4:19 PM EDT
Company Description
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.
The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.
GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp.
| Country | United States |
| Founded | 2017 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 1,000 |
| CEO | Katherine Stueland |
Contact Details
Address: North Tower, 6th Floor Stamford, Connecticut 06902 United States | |
| Phone | 888 729 1206 |
| Website | genedx.com |
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| Employer ID | 85-1966622 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | President, Chief Executive Officer and Director |
| Kevin Feeley | Chief Financial Officer |
| Karen Ponchner | Head of Operations |
| Eric Olivares Ph.D. | Chief Product and Technology Officer |
| Jami Biliboaca | Head of People Strategy |
| Paul Kruszka M.D. | Chief Medical Officer |
| Melanie Duquette | Chief Growth Officer |
| Sabrina Dunbar | Chief of Staff |
| Britt Johnson | Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2024 | 144 | Filing |
| Sep 16, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 9, 2024 | 144 | Filing |
| Sep 3, 2024 | 144 | Filing |
| Aug 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 30, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jul 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |